Most be nice to be so rich and look down on all us little people with a $2 million dollar house that his grandmother gave him that sits in her back yard. Of course he is studying porno science back their and trying to make a living. Kind of like Jared except he hadn't gotten famous yet🙄
From rdljllrdl Yahoo URL link article:
".....Biogen is working with an investment bank on the sale of the hemophilia assets, the people said this week. There is no guarantee that the discussions will lead to a sale, the people added.
These drugs collectively produced sales of about $500 million in 2015, the first full year in which they have been for sale..."
For Biogen to dump a "present" cash cow is to me indicative that they have bigger fish to fry in this treatment realm.
Both the Phase III trial and the OLE trial left untouched by the FDA for FAP. GSK kind of dropped the ball with not keeping in contact with the FDA. Some rumors that BIIB might want to sell their hemophilia division. They continue to move forward with IONS on the neurological front with 12 or 13 papers to be presented at the AAN. t
On the wrong board. Uses ethnic slurs, doesn't know a thing, defending ALNY all the way down from $140, now shorting IONS and getting very desperate as he may lose his mobile home. t
Most of what I say is info that is verifiable. Nothing hi/it says is verifiable. And the only real statement he said definitely is not verifiable. The only way to find out if he really is a koreholer.......you'd have to talk to his significant other to really find that out/know that. t
Bad typing, should be big commitment, and if you look at help wanted for BIIB it is really quite a show of confidence for the drug's approval and soon. t
Hello Pears, News is probably leaking out about the bug commitment BIIB is doing in regards to hiring specifically for the SMA drug. Improved chances for approval in the EU for this drug. t
Apparently you don't understand the concept of big money knowing things about to happen before the retail investor does. t
Pear, I know from the other board. Take care. And glad to see bcpiii here again. Not so glad th see President Putin still here. He doesn't have the Panama Papers, but rather abalienated arrogance. t
Is back again......but with much more crass language than the her. Mounting evidence of possility of IONS being a huge company down the road. Tidal wave to wash him away. t
There could very well be four phase IIII drugs to be reported on by the first half of 2017):
expected timeline for reporting top-line results from Phase 3 EPIC registration clinical trial of Plazomicin; expects completion of enrollment in Phase 3 EPIC study in 2016, top-line data in 1Q17 and NDA Submission in 2H17 (2.74)
Co announced the acceleration of the expected timeline for reporting results from the Company's ongoing Phase 3 EPIC registration clinical trial of plazomicin, the Company's lead product candidate being developed to treat serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE).
As a result of more rapid enrollment than anticipated, Achaogen now expects to release top-line results from the EPIC trial in the first quarter of 2017, two quarters ahead of initial estimates, and plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the second half of 2017.
He bet heavily on ALNY's success. He would attack anyone incessantly if they said anything bad about ALNY. He was defending it at $140 and all the way down. Because he thinks he knows about RNA technology he has shorted IONS heavily as a way to get his lost money back. He will lose again. t
IMO it is noise put out by GILD. It shouldn't change the outcome. MRK/IONS already got penalized by having that young head juror and misinformed jury where they were lead to believe that the price paid for Pharasset was an expense in developing and making the drug and counted that $11 billion purchase price of Pharmasset as an expense....really unheard of. They guy from MTSL is saying look for a 4-7% settlement on royalties. Of course GILD will look for an appeal. t